DURAVYU Falls Short on Primary Endpoint in LUGANO, Yet Secondary Results Offer a Silver Lining

summarizeSummary

DURAVYU missed the primary endpoint in the LUGANO Phase 3 trial for wet AMD, but showed strong secondary results including a 42% reduction in treatment burden. The company will rely on the LUCIA trial results in Q4 2026 to support an NDA filing.

check_boxKey Events · Product Development and Regulatory · EYPT

• Primary Endpoint Missed

  DURAVYU failed to achieve non-inferiority in mean change in BCVA versus aflibercept in the full LUGANO dataset, confounded by a 9-patient asymmetric cohort with vision loss unrelated to wet AMD.

• Ad Hoc Analysis Shows Non-Inferiority

  Excluding the 9-patient asymmetric cohort, DURAVYU achieved non-inferiority with a nominal p-value of 0.0096, with a mean change in BCVA of +5.9 letters versus +3.5 for aflibercept.

• Strong Secondary Endpoints

  DURAVYU demonstrated a 42% reduction in treatment burden (p<0.0001), 76% supplement-free rate up to Week 32, and 54% supplement-free up to Week 56, with only a 4-micron difference in central subfield thickness.

• Favorable Safety Profile

  No cases of insert migration, retinal vasculitis, or severe intraocular inflammation; low discontinuation rate of 6% through Week 56 in each arm.

auto_awesomeAnalysis · EYPT · Industrial Applications And Services

The lead drug candidate DURAVYU did not meet the primary endpoint of non-inferiority in visual acuity versus aflibercept in the full LUGANO Phase 3 trial dataset. However, an ad hoc analysis that excluded 9 patients with vision loss unrelated to wet AMD achieved non-inferiority, and compelling secondary endpoints included a 42% reduction in treatment burden and a favorable safety profile. These mixed results create significant uncertainty for the drug's regulatory path, with the next pivotal readout from the LUCIA trial expected in Q4 2026. The stock is trading near its 52-week low, reflecting the market's negative reaction to the primary endpoint miss.